Cingulate
Manufacturing · Kansas, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1901 W 47th Pl, Mission, Kansas, 66205, ...Phone Number
(913) 942-2300Website
www.cingulate.comRevenue
<$5 MillionStock Symbol
CINGIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Cingulate
Cingulate is a clinical stage biopharmaceutical company utilizing its proprietary Precision Timed Release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. Established in 2012, Cingulate is headquartered in Kansas City, Kansas, United States.Explore more
Cingulate Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Cingulate your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Cingulate has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Cingulate recently announced quarterly report
Website visits: Recent activity has been detected on your website
Cingulate, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Cingulate had a recent Job posting/layoffs
Product Launch: Get notified when Cingulate launches new products
Funding: Get notified immidiatlly once Cingulate has new funding data
Congratulate Masked Content for being promoted to Masked Content at Cingulate
Check out if Cingulate is spiking on competitors!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Cingulate
Compare insights from companies similar to Cingulate, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Cingulate is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Cingulate is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Cingulate.
Cingulate financials insights
Gather financial insights about Cingulate, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2013
Private Equity
$6.8M
2018
Private Equity
$7.5M
2020
Debt
$150K
2021
Debt
$237K
2024
Share Placement
$5M
2025
Debt
$6.6M
Cingulate Tech Stack
A closer look at the technologies used by Cingulate
See more technologies
Most Recent Scoops
Person-Based
Stake & Stock Ownership, Finance
Person-Based
Stake & Stock Ownership, Finance
Person-Based
Stake & Stock Ownership, Finance
Person-Based
Compliance
Person-Based
Finance, Investor Relations
Cingulate News & Media
Cingulate Announces Publication of Phase 3 ADHD Trial Results in Journal of Child and Adolescent Psychopharmacology
Publication helps establish the efficacy and safety profile of of CTx-1301, reinforcing the potential of Cingulate’s Precision Timed Release™ platform technology Publication helps establish the efficacy and safety profile of of CTx-1301, reinforcing the potential of Cingulate’s Precision Timed Release™ platform technologyCingulate Announces Publication of Phase 3 ADHD Trial Results in Journal of Child and Adolescent Psychopharmacology
Publication helps establish the efficacy and safety profile of of CTx-1301, reinforcing the potential of Cingulate’s Precision Timed Release™ platform technology Publication helps establish the efficacy and safety profile of of CTx-1301, reinforcing the potential of Cingulate’s Precision Timed Release™ platform technologyCingulate Inc. (NASDAQ: CING) Added to Russell 3000E®
CEO Shane Schaffer: Inclusion Demonstrates Continued Growth and Enhanced Visibility Among Institutional Investors CEO Shane Schaffer: Inclusion Demonstrates Continued Growth and Enhanced Visibility Among Institutional InvestorsCingulate Issued First U.S. Patent for Lead ADHD Asset CTx-1301
Exclusivity Extended into December 2042 Exclusivity Extended into December 2042
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Cingulate
Sign Up For FreeTo access detailed company insights
Cingulate is a clinical stage biopharmaceutical company utilizing its proprietary Precision Timed Release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and sub... Read More
